SENISCA appoints Tim Edwards as Chair of the Board Life-science leader with 30 years of experience to guide SENISCA towards becoming a clinical stage novel senotherapeutics company Exeter, UK — 10 September 2024: SENISCA SENISCA, a biotechnology...

SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...

SENISCA appoints Dr. Sarah Cole as Chief Executive Officer SENISCA appoints Dr. Sarah Cole as Chief Executive Officer Exeter, UK — 02 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and...

SENISCA shortlisted for 2022/2023 Nature Spinoff prize SENISCA shortlisted for 2022/2023 Nature Spinoff prize Exeter, UK – 25 May 2023: SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the...